More importantly, animal studies have shown that competitive inhibition of TGFβR2 activity using soluble TGFβR2 can ameliorate diabetic nephropathy 37, implying that TGFβR2 is an important target for diabetic complications. Here, TGFBR2 is linked to diabetic kidney disease.